The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design
Open accessAbstract
Falciparum malaria is initiated when Anopheles mosquitoes transmit the Plasmodium sporozoite stage during a blood meal. Irradiated sporozoites confer sterile protection against subsequent malaria infection in animal models and humans. This level of protection is unmatched by current recombinant malaria vaccines. However, the live-attenuated vaccine approach faces formidable obstacles, including development of accurate, reproducible attenuation techniques. We tested whether Plasmodium falciparum could be attenuated at the early liver stage by genetic engineering. The P. falciparum genetically attenuated parasites (GAPs) harbor individual deletions or simultaneous deletions of the sporozoite-expressed genes P52 and P36 . Gene deletions were done by double-cross-over recombination to avoid genetic reversion of the knockout parasites. The gene deletions did not affect parasite replication throughout the erythrocytic cycle, gametocyte production, mosquito infections, and sporozoite production rates. However, the deletions caused parasite developmental arrest during hepatocyte infection. The double-gene deletion line exhibited a more severe intrahepatocytic growth defect compared with the single-gene deletion lines, and it did not persist. This defect was assessed in an in vitro liver-stage growth assay and in a chimeric mouse model harboring human hepatocytes. The strong phenotype of the double knockout GAP justifies its human testing as a whole-organism vaccine candidate using the established sporozoite challenge model. GAPs might provide a safe and reproducible platform to develop an efficacious whole-cell malaria vaccine that prevents infection at the preerythrocytic stage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Malaria: progress, perils, and prospects for eradication
Greenwood, B. M., Fidock, D. A., Kyle, D. E., Kappe, S. H. I., Alonso, P. L., Collins, F. H., & Duffy, P. E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33996 · Cited by 709
Self-citation
Cited by
Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8 + T Cell Immunity
Epstein, J. E., Tewari, K., Lyke, K. E., Sim, B. K. L., Billingsley, P. F., Laurens, M. B., Gunasekera, A., Chakravarty, S., James, E. R., Sedegah, M., et al. (2011) · Science · doi:10.1126/science.1211548 · Cited by 533
Hepatitis E virus: advances and challenges
Nimgaonkar, I., Ding, Q., Schwartz, R. E., & Ploss, A. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.150 · Cited by 352
Is Parkinson's disease a prion disorder?
Olanow, C. W., & Prusiner, S. B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906759106 · Cited by 268
Nagaraj, V. A., Sundaram, B., Varadarajan, N. M., Subramani, P. A., Kalappa, D. M., Ghosh, S. K., & Padmanaban, G. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003522 · Cited by 159
Metadata
- Authors
- VanBuskirk, K. M., O'Neill, M. T., De La Vega, P., Maier, A. G., Krzych, U., Williams, J., Dowler, M. G., Sacci, J. B., Kangwanrangsan, N., Tsuboi, T., Kneteman, N. M., Heppner, D. G., Murdock, B. A., Mikolajczak, S. A., Aly, A. S. I., Cowman, A. F., & Kappe, S. H. I.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-08-04
- Volume
- 106
- Issue
- 31
- Pages
- 13004-13009
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2062137938
- Cited by
- 162
- References
- 1
- FWCI
- 18.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. https://app.cochat.ai/papers/10.1073/pnas.0906387106
- The paper
- VanBuskirk, K. M., O'Neill, M. T., De La Vega, P., Maier, A. G., Krzych, U., Williams, J., Dowler, M. G., Sacci, J. B., Kangwanrangsan, N., Tsuboi, T., Kneteman, N. M., Heppner, D. G., Murdock, B. A., Mikolajczak, S. A., Aly, A. S. I., Cowman, A. F., & Kappe, S. H. I. (2009). Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0906387106
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.